Computational systems analysis of dopamine metabolism

PLoS ONE

Volumn 3, Issue 6, 2008, Pages

  Qi, Zhen ^a,b   Miller, Gary W ^a,b   Voit, Eberhard O ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE TRANSPORTER;

ARTICLE; DOPAMINE METABOLISM; GENE EXPRESSION; GENE FUNCTION; HETEROZYGOSITY; HOMEOSTASIS; HUMAN; METABOLITE; MODEL; OXIDATIVE STRESS; SIMULATION; BIOLOGY; CORPUS STRIATUM; METABOLISM; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

COMPUTATIONAL BIOLOGY; CORPUS STRIATUM; DOPAMINE; HUMANS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

EID: 48949100951     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002444     Document Type: Article

References (65)

1. Olanow CW, Tatton WG (1999) Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22: 123-144.
2. von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, et al. (2005) Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 15: 473-490.
3. Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, et al. (1999) Degradation of alpha-synuclein by proteasome. J Biol Chem 274: 33855-33858.
4. Kawahara K, Hashimoto M, Bar-On P, Ho GJ, Crews L, et al. (2008) alpha-Synuclein aggregates interfere with Parkin solubility and distribution: ROLE IN THE PATHOGENESIS OF PARKINSON DISEASE. J Biol Chem 283: 6979-6987.
5. Goldstein DS (2007) Cardiac denervation in patients with Parkinson disease. Cleve Clin J Med 74 Suppl 1: S91-94.
6. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633-643.
7. Stokes AH, Hastings TG, Vrana KE (1999) Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 55: 659-665.
8. Yuan H, Zheng JC, Liu P, Zhang SF, Xu JY, et al. (2007) Pathogenesis of Parkinson's disease: oxidative stress, environmental impact factors and inflammatory processes. Neurosci Bull 23: 125-130.
9. Przedborski S (2005) Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord 11 Suppl 1: S3-7.
10. Quik M, McIntosh JM (2006) Striatal α6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy. J Pharmacol Exp Ther 316: 481-489.
11. Langmead CJ, Watson J, Reavill C (2008) Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 117: 232-243.
12. Sato K, Ueda H, Okumura F, Misu Y (1994) Supersensitization of intrastriatal dopamine receptors involved in opposite regulation of acetylcholine release in Parkinson's model rats. Neurosci Lett 173: 59-62.
13. Phillips JM, Lam HA, Ackerson LC, Maidment NT (2006) Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. Eur J Neurosci 23: 151-160.
14. Fernandez É, Schiappa R, Girault JA, Le Novère N (2006) DARPP-32 is a robust integrator of dopamine and glutamate signals. PLoS Comput Biol 2: e176.
15. Kaushik P, Gorin F, Vali S (2007) Dynamics of tyrosine hydroxylase mediated regulation or dopamine synthesis. J Comput Neurosci 22: 147-160.
16. Justice JB Jr., Nicolaysen LC, Michael AC (1988) Modeling the dopaminergic nerve terminal. J Neurosci Methods 22: 239-252.
17. Hakansson K, Lindskog M, Pozzi L, Usiello A, Fisone G (2004) DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia, Parkinsonism Relat Disord 10: 281-286.
18. Sun YF, Tang FM, Ding YM, Chen YT, Zhang GY, et al. (2001) Effect of dopamine depletion on DARPP-32 protein in ischemic rat striatum. Acta Pharmacol Sin 22: 243-248.
19. Barbano PE, Spivak M, Flajolet M, Nairn AC, Greengard P, et al. (2007) A mathematical tool for exploring the dynamics of biological networks. Proc Natl Acad Sci U S A 104: 19169-19174.
20. Lindskog M, Kim M, Wikstrom MA, Blackwell KT, Kotaleski JH (2006) Transient calcium and dopamine increase PKA activity and DARPP-32 phosphorylation. PLoS Comput Biol 2: e119.
21. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, et al. (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27: 29-34.
22. Schomburg I, Chang A, Hofmann O, Ebeling C, Ehrentreich F, et al. (2002) BRENDA: a resource for enzyme data and metabolic information. Trends Biochem Sci 27: 54-56.
23. Gesi M, Santinami A, Ruffoli R, Conti G, Fornai F (2001) Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties). Pharmacol Toxicol 89: 217-224.
24. Leuner K, Muller WE (2006) The complexity of the dopaminergic synapses and their modulation by antipsychotics. Pharmacopsychiatry 39 Suppl 1: S15-20.
25. Savageau MA (1969) Biochemical systems analysis. II. The steady-state solutions for an n-pool system using a power-law approximation. J Theor Biol 25: 370-379.
26. Savageau MA (1969) Biochemical systems analysis. I. Some mathematical properties of the rate law for the component enzymatic reactions. J Theor Biol 25: 365-369.
27. Savageau MA (1970) Biochemical systems analysis. 3. Dynamic solutions using a power-law approximation. J Theor Biol 26: 215-226.
28. Voit EO, ed (1991) Canonical Nonlinear Modeling. S-System Approach to Understanding Complexity. New YorkNY: Van Nostrand Reinhold. pp xi, 365.
29. Savageau MA (1976) Biochemical Systems Analysis: A Study of Function and Design in Molecular Biology. Reading MA: Addison-Wesley. pp 199.
30. Voit EO (2000) Computational analysis of biochemical systems: a practical guide for biochemists and molecular biologists. Cambridge, U.K.: Cambridge University Press. pp xii, 531.
31. Alvarez-Vasquez F, Sims KJ, Cowart LA, Okamoto Y, Voit EO, et al. (2005) Simulation and validation of modelled sphingolipid metabolism in Saccharomyces cerevisiae. Nature 433: 425-430.
32. Voit EO (2000) Canonical modeling: review of concepts with emphasis on environmental health. Environ Health Perspect 108 Suppl 5: 895-909.
33. Torres NV, Voit EO (2002) Pathway Analysis and Optimization in Metabolic Engineering. Cambridge, U.K.: Cambridge University Press. pp xiv + 305.
34. Savageau MA, Voit EO (1987) Recasting nonlinear differential equations as S-systems: a canonical nonlinear form. Math Biosci 87: 83-115.
35. Voit EO (1993) S-system modeling of complex systems with chaotic input. Environmetrics 4: 153-186.
36. Voit EO, Almeida J (2004) Decoupling dynamical systems for pathway identification from metabolic profiles. Bioinformatics 20: 1670-1681.
37. Schulz AR (1994) Enzyme Kinetics. From Diastase to Multi-enzyme Systems. Cambridge, U.K.: Cambridge University Press.
38. Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, et al. (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27: 8138-8148.
39. Sossi V, de la Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, et al. (2007) Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 62: 468-474.
40. Doudet DJ, Chan GL, Holden JE, Pate BD, Morrison KS, et al. (1997) Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA. Eur J Pharmacol 334: 31-38.
41. Barbeau A (1961) Dopamine and basal ganglia diseases. Arch Neurol 4: 97-102.
42. Sano I, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, et al. (1959) Distribution of catechol compounds in human brain. Biochim Biophys Acta 32: 586-587.
43. Carlsson A (1959) The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11: 490-493.
44. Anton AH, Sayre DF (1964) The Distribution of Dopamine and Dopa in Various Animals and a Method for Their Determination in Diverse Biological Material. J Pharmacol Exp Ther 145: 326-336.
45. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, et al. (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci U S A 95: 4029-4034.
46. Fumagalli F, Jones S, Bosse R, Jaber M, Giros B, et al. (1998) Inactivation of the dopamine transporter reveals essential roles of dopamine in the control of locomotion, psychostimulant response, and pituitary function. Adv Pharmacol 42: 179-182.
47. Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B (2006) Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet 15: 299-305.
48. Napolitano A, Zurcher G, Da Prada M (1995) Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur J Pharmacol 273: 215-221.
49. Chen K, Holschneider DP, Wu W, Rebrin I, Shih JC (2004) A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior. J Biol Chem 279: 39645-39652.
50. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, et al. (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci U S A 94: 9938-9943.
51. Huotari M, Santha M, Lucas LR, Karayiorgou M, Gogos JA, et al. (2002) Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J Pharmacol Exp Ther 303: 1309-1316.
52. Huotari M, Gogos JA, Karayiorgou M, Koponen O, Forsberg M, et al. (2002) Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 15: 246-256.
53. Kim DS, Szczypka MS, Palmiter RD (2000) Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J Neurosci 20: 4405-4413.
54. Colebrooke RE, Humby T, Lynch PJ, McGowan DP, Xia J, et al. (2006) Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease. Eur J Neurosci 24: 2622-2630.
55. Mooslehner KA, Chan PM, Xu W, Liu L, Smadja C, et al. (2001) Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol Cell Biol 21: 5321-5331.
56. Fernandez HH, Chen JJ (2007) Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin Neuropharmacol 30: 150-168.
57. Youdim MB, Bakhle YS (2006) Monamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147 Suppl 1: S287-296.
58. Stocchi F, Vacca L, Grassini P, De Pandis MF, Battaglia G, et al. (2006) Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 67: S24-29.
59. Tyce GM, Dousa MK, Muenter MD (1990) MAO and L-dopa treatment of Parkinson's disease. J Neural Transm Suppl 29: 233-239.
60. Shoulson I (1998) DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Ann Neurol 44: S160-166.
61. Matsunaga J, Sinha D, Pannell L, Santis C, Solano F, et al. (1999) Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. J Biol Chem 274: 3268-3271.
62. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, et al. (2003) Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 86: 1142-1148.
63. Kaur D, Peng J, Chinta SJ, Rajagopalan S, Di Monte DA, et al. (2007) Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging 28: 907-913.
64. Andersen JK (2004) Iron dysregulation and Parkinson's disease. J Alzheimers Dis 6: S47-52.
65. Alves R, Herrero E, Sorribas A (2004) Predictive reconstruction of the mitochondrial iron-sulfur cluster assembly metabolism: I. The role of the protein pair ferredoxin-ferredoxin reductase (Yah1-Arh1). Proteins 56: 354-366.